Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

TA 993

Known as: TA-993 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
In the present study, we investigated the effects of TA-993 and its metabolite MB3 on platelet activation in vitro. TA-993 and… 
2001
2001
In the present study, we investigated the effects of the antiplatelet agent TA-993 and its metabolite MB3 on the hemorheological… 
2000
2000
We investigated the antiplatelet mechanisms of TA-993 [(-)-cis-3-acetoxy-5-(2-(dimethylamino)ethyl)-2, 3-dihydro-8-methyl-2-(4… 
2000
2000
TA-993 (cis-(-)-2-(4-methylphenyl)-3-acetoxy-2,3-dihydro-5-(2-dimethylaminoethy l)-8-methyl1,5-benzothiazepine-4(5H)-one maleate… 
1999
1999
TA-993, (-)-cis-3-acetoxy-5-(2-(dimethylamino)ethyl)-2, 3-di-hydro-8-methyl-2-(4-methylphenyl)-1,5-benzothiazepin-4(5H)one… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
1998
1998
TA-993 is a new 1,5-benzothiazepine derivative having l-cis configuration and shows a potent antiplatelet aggregating action. We… 
1998
1998
TA-993 is a novel 1,5-benzothiazepine derivative of l-cis configuration, having a potent antiplatelet action and an increasing… 
1998
1998
TA-993, a new 1,5-benzothiazepine derivative having a l-cis configuration, has a selective increasing action on limb blood flow… 
1996
1996
TA-993, an l-cis 4',8-dimethyl derivative of the Ca2+ antagonist diltiazem, and some of its metabolites inhibited platelet… 
1995
1995
Since reported experimental models of thrombosis are not suitable for comparison of several drugs by oral administration, we…